These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22606012)

  • 1. Curcumin enhances cytotoxic effects of bortezomib in human multiple myeloma H929 cells: potential roles of NF-κB/JNK.
    Bai QX; Zhang XY
    Int J Mol Sci; 2012; 13(4):4831-4838. PubMed ID: 22606012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of curcumin in combination with bortezomib on proliferation and apoptosis of human multiple myeloma cell line H929 and its mechanism].
    Zhang XY; Bai QX; Huang GS; Zhao H; Chen JJ; Yang LJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):684-8. PubMed ID: 21729550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells.
    Zhen YZ; Lin YJ; Liu XJ; Shang BY; Zhen YS
    Anticancer Drugs; 2013 Jul; 24(6):609-16. PubMed ID: 23698252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
    Chauhan D; Li G; Podar K; Hideshima T; Mitsiades C; Schlossman R; Munshi N; Richardson P; Cotter FE; Anderson KC
    Blood; 2004 Oct; 104(8):2458-66. PubMed ID: 15217830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling.
    Yang Y; Ikezoe T; Saito T; Kobayashi M; Koeffler HP; Taguchi H
    Cancer Sci; 2004 Feb; 95(2):176-80. PubMed ID: 14965369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib.
    Walsby EJ; Pratt G; Hewamana S; Crooks PA; Burnett AK; Fegan C; Pepper C
    Mol Cancer Ther; 2010 Jun; 9(6):1574-82. PubMed ID: 20515939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib.
    Yu C; Rahmani M; Dent P; Grant S
    Exp Cell Res; 2004 May; 295(2):555-66. PubMed ID: 15093752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C.
    Li J; Xiang S; Zhang Q; Wu J; Tang Q; Zhou J; Yang L; Chen Z; Hann SS
    J Exp Clin Cancer Res; 2015 May; 34(1):46. PubMed ID: 25971429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs.
    Mujtaba T; Kanwar J; Wan SB; Chan TH; Dou QP
    Int J Mol Med; 2012 Jan; 29(1):102-6. PubMed ID: 22012631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of different concentrations of bortezomib on the expression of ERK, JNK and P38 in daunorubicin-resistant K562 cells].
    Fu BB; Fan Y; Hao LC; Liao AJ; Liu ZG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):671-5. PubMed ID: 21729547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptosis induced by trimethyltin chloride in human neuroblastoma cells SY5Y is regulated by a balance and cross-talk between NF-κB and MAPKs signaling pathways.
    Qing Y; Liang Y; Du Q; Fan P; Xu H; Xu Y; Shi N
    Arch Toxicol; 2013 Jul; 87(7):1273-85. PubMed ID: 23423712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
    Hideshima T; Ikeda H; Chauhan D; Okawa Y; Raje N; Podar K; Mitsiades C; Munshi NC; Richardson PG; Carrasco RD; Anderson KC
    Blood; 2009 Jul; 114(5):1046-52. PubMed ID: 19436050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.
    Berenson JR; Ma HM; Vescio R
    Semin Oncol; 2001 Dec; 28(6):626-33. PubMed ID: 11740821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial Expression of Concern: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
    Hideshima T; Podar K; Chauhan D; Ishitsuka K; Mitsiades C; Tai YT; Hamasaki M; Raje N; Hideshima H; Schreiner G; Nguyen AN; Navas T; Munshi NC; Richardson PG; Higgins LS; Anderson KC
    Oncogene; 2024 Sep; 43(40):3018. PubMed ID: 39209967
    [No Abstract]   [Full Text] [Related]  

  • 15. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model.
    Sung B; Kunnumakkara AB; Sethi G; Anand P; Guha S; Aggarwal BB
    Mol Cancer Ther; 2009 Apr; 8(4):959-70. PubMed ID: 19372569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin protects against hyperosmoticity-induced IL-1beta elevation in human corneal epithelial cell via MAPK pathways.
    Chen M; Hu DN; Pan Z; Lu CW; Xue CY; Aass I
    Exp Eye Res; 2010 Mar; 90(3):437-43. PubMed ID: 20026325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.
    Ishitsuka K; Hideshima T; Neri P; Vallet S; Shiraishi N; Okawa Y; Shen Z; Raje N; Kiziltepe T; Ocio EM; Chauhan D; Tassone P; Munshi N; Campbell RM; Dios AD; Shih C; Starling JJ; Tamura K; Anderson KC
    Br J Haematol; 2008 May; 141(5):598-606. PubMed ID: 18397345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.
    Manni S; Brancalion A; Mandato E; Tubi LQ; Colpo A; Pizzi M; Cappellesso R; Zaffino F; Di Maggio SA; Cabrelle A; Marino F; Zambello R; Trentin L; Adami F; Gurrieri C; Semenzato G; Piazza F
    PLoS One; 2013; 8(9):e75280. PubMed ID: 24086494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curcumin, a potential inhibitor of up-regulation of TNF-alpha and IL-6 induced by palmitate in 3T3-L1 adipocytes through NF-kappaB and JNK pathway.
    Wang SL; Li Y; Wen Y; Chen YF; Na LX; Li ST; Sun CH
    Biomed Environ Sci; 2009 Feb; 22(1):32-9. PubMed ID: 19462685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells.
    Park J; Ayyappan V; Bae EK; Lee C; Kim BS; Kim BK; Lee YY; Ahn KS; Yoon SS
    Mol Oncol; 2008 Dec; 2(4):317-26. PubMed ID: 19383353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.